Surrozen News and Activities
Presence
Surrozen is a biotechnology company that develops regenerative medicines for serious diseases. Its main work includes drug discovery and clinical development for patients, healthcare providers, and partners in liver, eye, and intestinal conditions.
Surrozen products and services overview:
- Regenerative medicines
- Drug discovery
- Clinical development
- Liver disease therapies
- Eye disease therapies
- Intestinal disease therapies
Revenue: ~$10 million
Employees: 45
Headquarters: South San Francisco, United States (USA)
Surrozen is one of the...
Surrozen is a company listed under the stock ticker SRZN (US).
Executives
View the org chart displaying its 24 main executives
Most searched biographies at Surrozen
- Craig Parker, Chief Executive Officer and Director
- Mary Haak-Frendscho, Director
- Anna Berkenblit, Director
Popular executive movements at Surrozen
- Andrew Maleki will join the company as Chief Financial Officer on Nov. 12, 2025 (posted on November 10 2025).
Create your alert
to follow the executive moves at Surrozen.
Biotechnology
Surrozen has 2,432 competitors including Vertex Pharmaceuticals (United States (USA)), Lonza (Switzerland) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Crystalys Therapeutic has just announced a $130 Million fundraising (posted on July 23 2026).
- Ipsen has acquired Memo Therapeutics (posted on July 22 2026).
- AdvanCell has just announced a $315 Million fundraising (posted on July 21 2026).
Popular contacts in Biotechnology
News
Press releases by Surrozen
- Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis | Surrozen
- Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW) | Surrozen
- Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis | Surrozen
- Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise
- Surrozen Reports First Quarter 2022 Financial Results | Surrozen
- Surrozen to Present at the BofA Securities 2022 Healthcare Conference | Surrozen
- Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting | Surrozen
- Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results | Surrozen
- Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline | Surrozen
- Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference | Surrozen
- View more press releases Close
Social media about Surrozen
- Surrozen on Wikipedia, Google News & Yahoo Finance
- Surrozen on LinkedIn, X (Twitter) & YouTube
